Unraveling the scissile bond: How ADAMTS13 recognizes and cleaves von Willebrand factor

Blood

Volumn 118, Issue 12, 2011, Pages 3212-3221

  Crawley, James T B ^a   De Groot, Rens ^a   Xiang, Yaozu ^a   Luken, Brenda M ^a   Lane, David A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; CALCIUM ION; COLLAGEN; CYSTEINE; FURIN; GLOBULAR PROTEIN; GLUTAMIC ACID; GLYCAN; GLYCOPROTEIN IB ALPHA; HISTIDINE; METALLOPROTEINASE; SPACER DNA; THROMBIN; THROMBOSPONDIN 1; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ZINC ION;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; BLOOD CLOTTING; BLOOD VESSEL INJURY; CALCIUM BINDING; CARBOXY TERMINAL SEQUENCE; DELETION MUTANT; DIMERIZATION; ENDOPLASMIC RETICULUM; ENDOTHELIUM CELL; ENZYME STRUCTURE; ENZYME SYNTHESIS; GLYCOSYLATION; GOLGI COMPLEX; HUMAN; MUTATION; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN MULTIMERIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN UNFOLDING; REVIEW; SCISSILE BOND; SHEAR STRESS; STELLATE CELL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM; WEIBEL PALADE BODY;

EID: 80053146780     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-306597     Document Type: Review

References (84)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. (Pubitemid 28411134)
2. Ruggeri ZM, De Marco L, Gatti L, Bader R, Montgomery RR. Platelets have more than one binding site for von Willebrand factor. J Clin Invest. 1983;72(1):1-12. (Pubitemid 13026623)
3. Bockenstedt P, Greenberg JM, Handin RI. Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen: effects of disulfide reduction and limited proteolysis of polymeric von Willebrand factor. J Clin Invest. 1986; 77(3):743-749. (Pubitemid 16067944)
4. Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites within human von Willebrand factor for monomeric type III collagen. Biochemistry. 1986;25(26):8357-8361. (Pubitemid 17003933)
5. Hamer RJ, Koedam JA, Beeser-Visser NH, Bertina RM, Van Mourik JA, Sixma JJ. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem. 1987;166(1):37-43. (Pubitemid 17089108)
6. Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol Chem. 1989;264(29): 17361-17367. (Pubitemid 19255569)
7. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78(6):1456-1461. (Pubitemid 17219507)
8. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Sheardependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88(8):2939-2950. (Pubitemid 26357374)
9. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994;83(8):2171-2179. (Pubitemid 24112728)
10. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A. 2007;104(19):7899-7903. (Pubitemid 47185848)
11. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87(10):4223-4234. (Pubitemid 26152266)
12. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87(10):4235-4244.
13. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494. (Pubitemid 32938741)
14. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-18.
15. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood. 1997;89(6): 1954-1962. (Pubitemid 27132110)
16. Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost. 2008;6(4):583-588. (Pubitemid 351418945)
17. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 2007;109(5):1998-2000. (Pubitemid 46348198)
18. Studt JD, Hovinga JA, Antoine G, et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood. 2005;105(2):542-544. (Pubitemid 40070733)
19. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104(1):100-106. (Pubitemid 38879844)
20. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005;105(3):1085-1093. (Pubitemid 40170879)
21. Lam JK, Chion CK, Zanardelli S, Lane DA, Crawley JT. Further characterization of ADAMTS-13 inactivation by thrombin. J Thromb Haemost. 2007;5(5):1010-1018. (Pubitemid 46691731)
22. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factorcleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107(2):528-534. (Pubitemid 43076375)
23. Feys HB, Vandeputte N, Palla R, et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(9):2053-2062.
24. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel- Palade bodies of human endothelial cells. J Cell Biol. 1982;95(1):355-360. (Pubitemid 13208536)
25. Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest. 1985;76(3):1102-1106. (Pubitemid 16225558)
26. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol. 1984;99(6):2123-2130. (Pubitemid 15181875)
27. Katsumi A, Tuley EA, Bodo I, Sadler JE. Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor. J Biol Chem. 2000;275(33):25585-25594.
28. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci U S A. 1992;89(8):3531-3535.
29. Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell. 1988;52(2):229-236. (Pubitemid 18043596)
30. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008; 111(6):3042-3049.
31. McKinnon TA, Goode EC, Birdsey GM, et al. Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor. Blood. 2010;116(4):640-648.
32. Canis K, McKinnon TA, Nowak A, et al. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost. 8(1):137-145.
33. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood. 2005;106(6):1988-1991. (Pubitemid 41291710)
34. Schulte am Esch J 2nd, Robson SC, Knoefel WT, Eisenberger CF, Peiper M, Rogiers X. Impact of O-linked glycosylation of the VWF-A1-domain flanking regions on platelet interaction. Br J Haematol. 2005;128(1):82-90.
35. Wagner DD, Saffaripour S, Bonfanti R, et al. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991;64(2): 403-413. (Pubitemid 121001264)
36. Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood. 2008;112(4):957-964.
37. Dong JF, Moake JL, Nolasco L, et al. ADAMTS- 13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100(12):4033-4039. (Pubitemid 35396870)
38. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009;324(5932):1330-1334.
39. Kim J, Zhang CZ, Zhang X, Springer TA. A mechanically stabilized receptor-ligand flex-bond important in the vasculature. Nature. 2010; 466(7309):992-995.
40. Wu T, Lin J, Cruz MA, Dong JF, Zhu C. Force-induced cleavage of single VWFA1A2A3 tridomains by ADAMTS-13. Blood. 2010;115(2):370-378.
41. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005;106(3):922-924. (Pubitemid 41076434)
42. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 2006;4(6): 1396-1404.
43. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001; 98(6):1662-1666.
44. Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem (Tokyo). 2001;130(4):475-480. (Pubitemid 33021590)
45. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276(44): 41059-41063.
46. Gerhardt S, Hassall G, Hawtin P, et al. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J Mol Biol. 2007;373(4):891-902. (Pubitemid 47505246)
47. Mosyak L, Georgiadis K, Shane T, et al. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci. 2008;17(1):16-21.
48. Shieh HS, Mathis KJ, Williams JM, et al. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J Biol Chem. 2008;283(3):1501-1507.
49. Anderson PJ, Kokame K, Sadler JE. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem. 2006;281(2):850-857.
50. Gardner MD, Chion CK, De Groot R, Shah A, Crawley JT, Lane DA.Afunctional calcium-binding site in the metalloprotease domain of ADAMTS13. Blood. 2009;113(5):1149-1157.
51. Takeda S. Three-dimensional domain architecture of the ADAM family proteinases. Semin Cell Dev Biol. 2009;20(2):146-152.
52. Akiyama M, Takeda S, Kokame K, Takagi J, Miyata T. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci U S A. 2009;106(46):19274-19279.
53. Davis AK, Makar RS, Stowell CP, Kuter DJ, Dzik WH. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion. 2009;49(2):206-213.
54. Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 2003;102(9):3232-3237. (Pubitemid 37314760)
55. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem. 2003;278(32):30136-30141. (Pubitemid 36962406)
56. Ai J, Smith P, Wang S, Zhang P, Zheng XL. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem. 2005;280(33):29428-29434. (Pubitemid 41177015)
57. Tao Z, Wang Y, Choi H, et al. Cleavage of ultralarge multimers of von Willebrand factor by Cterminal- truncated mutants of ADAMTS-13 under flow. Blood. 2005;106(1):141-143. (Pubitemid 40967185)
58. Zhang P, Pan W, Rux AH, Sachais BS, Zheng XL. The cooperative activity between the carboxylterminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood. 2007;110(6):1887-1894. (Pubitemid 47443901)
59. Zhou W, Bouhassira EE, Tsai HM. An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers. Blood. 2007;110(3):886-893. (Pubitemid 47267425)
60. De Maeyer B, De Meyer SF, Feys HB, et al. The distal carboxyterminal domains of murine ADAMTS13ba influence proteolysis of platelet-decorated VWF strings in vivo. J Thromb Haemost. 2010;8(10):2305-2312.
61. Tao Z, Peng Y, Nolasco L, et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood. 2005;106(13):4139-4145. (Pubitemid 41775919)
62. Zanardelli S, Chion AC, Groot E, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood. 2009;114(13):2819-2828.
63. Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus EM, Sadler JE. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost. 2009;7(12):2088-2095.
64. Crawley JT, De Groot R, Luken BM. Circulating ADAMTS-13-von Willebrand factor complexes: an enzyme on demand. J Thromb Haemost. 2009;7(12):2085-2087.
65. Banno F, Chauhan AK, Kokame K, et al. The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood. 2009;113(21):5323-5329.
66. Banno F, Kaminaka K, Soejima K, Kokame K, Miyata T. Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease. J Biol Chem. 2004;279(29):30896-30903. (Pubitemid 38938026)
67. Zhang Q, Zhou YF, Zhang CZ, Zhang X, Lu C, Springer TA. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A. 2009;106(23):9226-9231.
68. Zanardelli S, Crawley JT, Chion CK, Lam JK, Preston RJ, Lane DA. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem. 2006;281(3):1555-1563.
69. Luken BM, Winn LY, Emsley J, Lane DA, Crawley JT. The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function. Blood. 2010;115(23):4910-4913.
70. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood. 2008;111(2):651-657.
71. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood. 2004;103(2):607-612. (Pubitemid 38140094)
72. Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE. Exosite interactions contribute to tension- induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci U S A. 2006;103(50): 19099-19104. (Pubitemid 350002834)
73. Wu JJ, Fujikawa K, McMullen BA, Chung DW. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci U S A. 2006;103(49): 18470-18474. (Pubitemid 44913434)
74. Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103(12):4514-4519. (Pubitemid 38745978)
75. Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood. 2010; 115(8):1640-1649.
76. Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood. 2010; 115(11):2300-2310.
77. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood. 2008;112(5):1713-1719.
78. De Groot R, Bardhan A, Ramroop N, Lane DA, Crawley JT. Essential role of the disintegrin-like domain in ADAMTS13 function. Blood. 2009; 113(22):5609-5616.
79. Pruss CM, Notley CR, Hegadorn CA, O'Brien LA, Lillicrap D. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor. Br J Haematol. 2008;143(4):552-558.
80. Xiang Y, De Groot R, Crawley JT, Lane DA. Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type I motif, member 13 (ADAMTS13) [published online ahead of print June 24, 2011]. Proc Natl Acad Sci U S A. doi:10.1073/pnas.1018559108.
81. De Groot R, Lane DA, Crawley JT. The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. Blood. 2010;116(16):3064-3072.
82. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100. (Pubitemid 40524057)
83. Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha- (1-289): slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem. 2000; 275(11):7539-7546. (Pubitemid 30159651)
84. Shida Y, Nishio K, Sugimoto M, et al. Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood. 2008; 111(3):1295-1298. (Pubitemid 351213413)